Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · IEX Real-Time Price · USD
21.82
-0.20 (-0.91%)
At close: Jul 19, 2024, 4:00 PM
21.86
+0.04 (0.18%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $287.53M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $64.49M. In the year 2023, Fulgent Genetics had annual revenue of $289.21M.
Revenue (ttm)
$287.53M
Revenue Growth
-21.20%
P/S Ratio
2.27
Revenue / Employee
$242,846
Employees
1,184
Market Cap
652.95M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
Dec 31, 2019 | 32.53M | 11.18M | 52.35% |
Dec 31, 2018 | 21.35M | 2.62M | 13.99% |
Dec 31, 2017 | 18.73M | 454.00K | 2.48% |
Dec 31, 2016 | 18.28M | 8.70M | 90.85% |
Dec 31, 2015 | 9.58M | 8.30M | 649.30% |
Dec 31, 2014 | 1.28M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Aveanna Healthcare Holdings | 1.92B |
Definitive Healthcare | 255.69M |
Paragon 28 | 225.44M |
SIGA Technologies | 157.02M |
Arcturus Therapeutics Holdings | 124.53M |
UroGen Pharma | 84.30M |
Exscientia | 25.14M |
FLGT News
- 10 days ago - Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024 - Business Wire
- 6 weeks ago - Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing - GlobeNewsWire
- 6 weeks ago - Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer - Business Wire
- 2 months ago - Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting - Business Wire
- 2 months ago - Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics - Business Wire
- 2 months ago - Fulgent Reports First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024 - Business Wire
- 5 months ago - Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire